TearLab Corporation (NASDAQ:TEAR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Tuesday. They currently have a $4.00 price target on the medical research company’s stock. HC Wainwright’s target price suggests a potential upside of 150.00% from the company’s previous close.

Several other equities research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of TearLab Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th. Rodman & Renshaw reduced their target price on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 16th. Five research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $4.95.

TearLab Corporation (NASDAQ TEAR) traded down 1.84% on Tuesday, hitting $1.60. 135,124 shares of the stock were exchanged. The company’s 50 day moving average is $2.10 and its 200 day moving average is $2.81. TearLab Corporation has a 1-year low of $1.53 and a 1-year high of $8.20. The stock’s market cap is $9.19 million.

TearLab Corporation (NASDAQ:TEAR) last announced its quarterly earnings results on Monday, August 14th. The medical research company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The business had revenue of $7 million during the quarter, compared to the consensus estimate of $6.86 million. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.08) EPS. On average, equities research analysts expect that TearLab Corporation will post ($2.70) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/15/hc-wainwright-analysts-give-tearlab-corporation-tear-a-4-00-price-target.html.

TearLab Corporation Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.